2024/03/29
Tokyo Metropolitan Neurological Hospital, Tokyo Metropolitan Health and Hospitals Corporation
Keio University
Tokai University
National Center of Neurology and Psychiatry (NCNP), National Research and Development Agency
A research group led by Dr. Akinori Uruha, Chief of Neurology at Tokyo Metropolitan Neurological Hospital, and Dr. Munenori Oyama, Assistant Professor in the Department of Neurology at the Keio University School of Medicine, and consisting of members from Tokai University, the National Center of Neurology and Psychiatry (NCNP), and institutions in Germany and France, has clarified the characteristics of Ku antibodies in polymyositis/dermatomyositis (myositis). The research findings were published in the online edition of "Neurology," the journal of the American Academy of Neurology, on March 29, 2024 (Japan Standard Time).
This study is the first in the world to reveal the previously unclarified characteristics of myositis associated with Ku antibodies. Since Ku antibodies cannot be measured in routine clinical practice, cases may be overlooked, highlighting the need to establish a testing system. This research is expected to further advance the understanding of the pathophysiology of myositis, leading to the future development of personalized treatments tailored to each patient.
For the full press release, please see below.